588940-69-6

Basic information

• Product Name: (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide
• Synonyms: (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide
• CAS NO: 588940-69-6
• Molecular Weight: 363.908
• Mol File: 588940-69-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide(588940-69-6)
• EPA Substance Registry System: (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide(588940-69-6)

Safety Data

• Hazardous Substances Data: 588940-69-6(Hazardous Substances Data)

Upstream product

• 17733-22-1 2-chlorothioanisole 
• 393165-02-1 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester 
• 321-97-1 (1R,2R)-pseudoephedrine 
• 87776-75-8 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 625113-43-1 2(R)-(3-chloro-4-methylsulfanyl-phenyl)-3-(2-hydroxycyclopentyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenylethyl]-N-methyl-proprionamide 
• 1393926-51-6 2(R)-(3-chloro-4-methylsulfanylphenyl)-N-methyl-N-[1(R)-methyl-2-oxo-2(R)-phenylethyl]-3-(2-oxocyclopentyl)proprionamide 
• 625113-52-2 (2R)-2-(3-chloro-4-methanesulfonylphenyl)-3-(2-oxocyclopentyl)propanoic acid 
• 625114-41-2 Piragliatin 
• 625114-00-3 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-(3-formyloxy-cyclopentyl)propionic acid 
• 625114-43-4 (2R)-2-(3-chloro-4-methanesulfonylphenyl)-3-[(1R)-3-oxocyclopentyl]propanoic acid 
• 588940-80-1 (2R)-2-[3-chloro-4-(methylsulfanyl)phenyl]-3-cyclopentylpropanoic acid 
• 300356-14-3 (R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-3-cyclopentylpropanoic acid 
• 588941-45-1 RO 0505082 

Relevant articles and documents

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.